Mouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland.
Laboratory of Proteomics and Analytical Technologies, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland.
Cancer Res. 2018 Feb 15;78(4):891-908. doi: 10.1158/0008-5472.CAN-17-2353. Epub 2017 Dec 19.
The precise characteristics that distinguish normal and oncogenic RAS signaling remain obscure. Here, we show that oncogenic RAS and BRAF induce perinuclear relocalization of several RAS pathway proteins, including the kinases CK2 and p-ERK1/2 and the signaling scaffold KSR1. This spatial reorganization requires endocytosis, the kinase activities of MEK-ERK and CK2, and the presence of KSR1. CK2α colocalizes with KSR1 and Rab11, a marker of recycling endosomes, whereas p-ERK associates predominantly with a distinct KSR1-positive endosomal population. Notably, these perinuclear signaling complexes (PSC) are present in tumor cell lines, mouse lung tumors, and mouse embryonic fibroblasts undergoing RAS-induced senescence. PSCs are also transiently induced by growth factors (GF) in nontransformed cells with delayed kinetics (4-6 hours), establishing a novel late phase of GF signaling that appears to be constitutively activated in tumor cells. PSCs provide an essential platform for RAS-induced phosphorylation and activation of the prosenescence transcription factor C/EBPβ in primary MEFs undergoing senescence. Conversely, in tumor cells, C/EBPβ activation is suppressed by 3'UTR-mediated localization of transcripts to a peripheral cytoplasmic domain distinct from the PSC region. Collectively, our findings indicate that sustained PSC formation is a critical feature of oncogenic RAS/BRAF signaling in cancer cells that controls signal transmission to downstream targets by regulating selective access of effector kinases to substrates such as C/EBPβ. In addressing the long-standing question of the difference between normal and oncogenic RAS pathway signaling, this study shows that oncogenic RAS specifically triggers constitutive endocytosis-dependent movement of effector kinases to a perinuclear region, thereby creating connections to unique downstream targets such as the core prosenescence and the inflammatory regulatory transcription factor C/EBPβ. .
正常和致癌 RAS 信号之间的确切特征仍然不清楚。在这里,我们表明致癌 RAS 和 BRAF 诱导几种 RAS 途径蛋白的核周重新定位,包括激酶 CK2 和 p-ERK1/2 以及信号支架 KSR1。这种空间重排需要内吞作用、MEK-ERK 和 CK2 的激酶活性以及 KSR1 的存在。CK2α 与 KSR1 和 Rab11 共定位,Rab11 是回收性内体的标志物,而 p-ERK 主要与不同的 KSR1 阳性内体群相关联。值得注意的是,这些核周信号复合物(PSC)存在于肿瘤细胞系、小鼠肺肿瘤和发生 RAS 诱导衰老的小鼠胚胎成纤维细胞中。PSC 也可被生长因子(GF)短暂诱导,在非转化细胞中具有延迟的动力学(4-6 小时),建立了一个新的 GF 信号晚期阶段,该阶段在肿瘤细胞中似乎持续激活。PSC 为 RAS 诱导的原衰老转录因子 C/EBPβ在经历衰老的原代 MEF 中的磷酸化和激活提供了一个必要的平台。相反,在肿瘤细胞中,C/EBPβ 的激活被 3'UTR 介导的转录本定位于与 PSC 区域不同的外周细胞质区域而受到抑制。总的来说,我们的研究结果表明,持续的 PSC 形成是致癌 RAS/BRAF 信号在癌细胞中的一个关键特征,它通过调节效应激酶对 C/EBPβ 等下游靶标的选择性进入来控制信号传递。在解决正常和致癌 RAS 途径信号之间长期存在的问题时,本研究表明致癌 RAS 特异性触发效应激酶的组成型内吞依赖性运动到核周区域,从而与独特的下游靶标(如核心原衰老和炎症调节转录因子 C/EBPβ)建立联系。